P1826 - Hepatic Fibrosis Improvement Does Not Differ Between Type of Antiviral Therapy in Chronic Hepatitis B Patients

Monday, October 25, 2021

10:30 AM – 4:15 PM PT

Location: Shoreline Exhibit Hall

Has Audio

Presenting Author(s)

QP

Quynh-An Phan, BS

Liver Associates of Texas, PA
Houston, TX, United States

Quynh-An Phan, BS¹, Ana Romero, MD¹, Sadde Mohamed, BS¹, Natalie N. Nguyen, BS², Miriam M. Sanchez, MD¹, Chukwuma Egwim, MD³, Victor Ankoma-Sey, MD¹
¹Liver Associates of Texas, PA, Houston, TX; ²Baylor College of Medicine, Houston, TX; ³Liver Assosciates of Texas, PA, Houston, TX

Introduction: Chronic Hepatitis B infection (HBV) is the most common viral hepatitis infection worldwide. HBV can result in progressive liver injury culminating in significant inflammation and fibrosis. The aim of this study is to assess the effectiveness of various antiviral therapies on hepatic fibrosis in chronic HBV infection using noninvasive markers in a community setting.

Methods: A retrospective study was conducted in chronic HBV patients seen at the Liver Associates of Texas Hepatology clinics in Houston, Texas, seen from 1/2018 to 5/2021. Epidemiological and clinical data of HBV patients treated with entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide were analyzed. APRI and FIB-4 scores, which are noninvasive markers of fibrosis, were calculated for all patients at baseline (before treatments) and 6 months post sustained virologic response (SVR). A repeated measures ANOVA analysis was used to assess fibrosis trends between the three treatments and within a single treatment group.

Results: A total of 123 patients were reviewed. 64.2% of patients were male, with the mean age of 54.0 years. The ethnic breakdown was: 56.9% Asian, 24.4% African-American, 8.1% White, 4.9% Hispanic, 0.8% Native Hawaiian/Pacific Islander, and 4.9% Unknown. 85 patients received treatment, with 20 patients receiving entecavir, 29 tenofovir alafenamide, and 36 tenofovir disoproxil fumarate. Both APRI and FIB-4 scores showed a statistically significant difference from before treatment to 6 months post treatment independent of treatment type(APRI: p= 0.035; FIB-4: p= 0.037). Post-hoc analysis showed a statistical significant decrease from baseline to 5 months post initiation of treatment for both APRI (Mean difference = 0.229, p_bonferroni= 0.035) and FIB4 (mean difference = 0.168, p_bonferroni = 0.037). There was no statistical significant interactions between treatment type and FIB4 or APRI scores.

Discussion: This study demonstrated that in patients with Hepatitis B, there was a statistically significant improvement in hepatic fibrosis within 6 months of antiviral therapy initiation and that there is no significant difference in using any of the three types of antiviral treatments: entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide in this population of HBV patients.

Figure: Title: APRI scores over time in patients treated with Entecavir, Viread, and Vemlidy.

Legend: Blue = entecavir. Gray = tenofovir alafenamide, Yellow = tenofovir disoproxil fumarate

	Sum of Square	Df	Mean Square	F	p-value	η²_p
APRI
Time	2.111	1	2.111	4.585	0.035*	0.053
Time ✻ Treatment	0.637	2	0.318	0.691	0.504	0.017
Residual	37.754	82	0.460
FIB4
Time	1.13	1	1.128	4.52	0.037*	0.052
Time ✻ Treatment	1.01	2	0.504	2.02	0.139	0.047
Residual	20.46	82	0.249
Post Hoc Analysis
			Mean Difference	SE	Df	p_bonferroni
APRI
Baseline – 6 months post SVR			0.229	0.107	82	0.035*
FIB4
Baseline – 6 months post SVR			0.168	0.0789	82	0.037*

Table: Table 1. APRI and FIB4 in patients treated with Entecavir, Viread, and Vemlidy. Df= degrees of freedom, F= F-statistics, SE = standard error, η²p = Partial η²

Disclosures:

Quynh-An Phan indicated no relevant financial relationships.

Ana Romero indicated no relevant financial relationships.

Sadde Mohamed indicated no relevant financial relationships.

Natalie Nguyen indicated no relevant financial relationships.

Miriam Sanchez indicated no relevant financial relationships.

Chukwuma Egwim: Allergan plc – Grant/Research Support. Genfit – Grant/Research Support. Gilead Sciences – Other Financial or Material Support, Speaking/Teaching. Intercept Pharmaceuticals – Grant/Research Support. Madrigal Pharmaceuticals – Grant/Research Support. NorthSea Therapeutics – Grant/Research Support.

Victor Ankoma-Sey: Abbvie – Other Financial or Material Support, Speaking/Teaching. Allergan plc – Grant/Research Support. Genfit – Grant/Research Support. Gilead Sciences – Other Financial or Material Support, Speaking/Teaching. Intercept Pharmaceuticals – Grant/Research Support, Other Financial or Material Support, Speaking/Teaching. Madrigal Pharmaceuticals – Grant/Research Support. NorthSea Therapeutics – Grant/Research Support.

Quynh-An Phan, BS¹, Ana Romero, MD¹, Sadde Mohamed, BS¹, Natalie N. Nguyen, BS², Miriam M. Sanchez, MD¹, Chukwuma Egwim, MD³, Victor Ankoma-Sey, MD¹. P1826 - Hepatic Fibrosis Improvement Does Not Differ Between Type of Antiviral Therapy in Chronic Hepatitis B Patients, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.